ABGENIX TO RECEIVE MILESTONE PAYMENT FROM CHIRON FOR ADVANCEMENT OF ONCOLOGY ANTIBODY

Abgenix will receive a milestone payment from Chiron triggered by Chiron's filing of an investigational new drug (IND) application with the FDA for the novel oncology compound CHIR-12.12, a fully human antagonist antibody targeting CD40. The antibody was created by Chiron using proprietary XenoMouse technology licensed from Abgenix.
BC Technology